Phase 3 N=40 Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome
Marfan Syndrome
Primary: Aortic Biophysical Properties - Pulse Wave Velocity — -1.15; -0.22 change in meters/second
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=608 Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome
Marfan Syndrome
Primary: Annual Rate of Change in Aortic Root (Sinuses of Valsalva) Body-surface-area-adjusted Z-score — -0.139; -0.107 z-score/year — p=0.08
Phase 3 N=30 Comparison of Aliskiren vs Negative Controls on Aortic Stiffness in Patients With MFS
Marfan Syndrome
Primary: Central Aortic Distensibility by MRI — 3.7; 4.7; 5.7; 5.1 (mmHg ^ -1) x 10 ^ -3
N/A N=11 Familial Hyperlipidemia Family Registry
Familial Hyperlipidemia
Primary: Familial Hypercholesterolemia (FH) Determination for Family Members of School Children With Elevated Cholesterol and Documented FH Variant — 3; 8 participants
N/A N=116 Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS)
Metabolic Syndrome X · Overweight · Hypertension
Primary: Change in Carotid Intima-media Thickness From Baseline to Year 1 — 0.766; 0.765; 0.758; 0.768 millmeter — p=0.7279
N/A N=1,147 Carotid Structure and Function in MPS Syndromes: A Multicenter Study of the Lysosomal Disease Network
Mucopolysaccharidoses
Primary: Carotid Intima-media Thickness, Measured in Millimeters — 0.44; 0.52; 0.56 mm
Phase 2 N=34 Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction
Metabolic Syndrome · Coronary Microvascular Dysfunction
Primary: Absolute Change in Coronary Cross-sectional Area (in mm²) Within the Vericiguat Group as Assessed by Magnetic Resonance Imaging (MRI) — -1.11; 0.40 mm^2 — p=0.0005
N/A N=29 Calcium Absorption in Patients With Rothmund-Thomson Syndrome
Rothmund-Thomson Syndrome
Primary: Bone Density (Low Areal Bone Mineral Density (aBMD)) — -1.3; -0.9; -2.4; -1.2 z-score
N/A N=36 Exercise,Metabolic Syndrome and Weight Regain (Echocardiography Substudy)
Metabolic Syndrome · Obesity
Primary: Mean Resting E/E' — 7.01 ml/min/kg — p==0.14
Phase 4 N=53 Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy
Myocardial Fibrosis · Hypertrophic Cardiomyopathy
Primary: Absolute Change in Serum Markers of Collagen Turnover (Micrograms/L) Over a One-year Follow-up Period in the Spironolactone Group Compared to Placebo. — 2.1; 2.1; 0.7…
N/A N=12 Metabolic Syndrome and Fall Risk
Metabolic Syndrome · Autonomic Neuropathy
Primary: Four Square Step Test (FSST) — 11.04; 14.29 seconds
Phase 3 N=40 The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome
Metabolic Syndrome
Primary: Flow Mediated Vasodilation — 9.5; 10.8; 10.5; 10.9 percentage of vasodilation